CHMP turns down Lilly’s Emgality for cluster headache

Lilly's migraine drug gets key cluster headache approval

The FDA has approved Eli Lilly’s Emgality (galcanezumab-gnlm) for the treatment of episodic cluster headache in adults, giving the calcitonin gene-related peptide (CGRP) antibody a key poin

Lilly claims fast FDA review for Emgality in cluster headach...

Eli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality but could get a leg-up with an indication in episodic cluster headache.<

Lilly drug scrapes through cluster headache trial

FDA to make decision on Amgen drug tomorrow